HSTO - Histogen files IND application for regenerative human matrix

Histogen ([[HSTO]] -4.0%) has submitted an Investigational New Drug ((IND)) application with the FDA for the initiation of a Phase 1/2 trial to evaluate HST-003, extracellular matrix.The study will assess the safety and efficacy of human  implanted within microfracture interstices and the cartilage defect in the knee to regenerate hyaline cartilage in combination with a microfracture procedure.Assuming the HST-003 IND is approved, Phase 1/2 trial is expected to initiate in Q1 of 2021.

For further details see:

Histogen files IND application for regenerative human matrix